MAPS opposes the DEA's attempt to place five lesser-known tryptamines into Schedule I under the Controlled Substances Act

MAPS opposes the DEA's renewed attempt to place five lesser-known psychedelic tryptamines - 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT - into Schedule I of the Controlled Substances Act. The organization says Schedule I would restrict research into potential benefits while criminalizing personal use, without evidence in the DEA's record showing a level of public harm that warrants either outcome. MAPS notes that the agency withdrew an earlier version of the same action in 2022 after objections from researchers and legal advocates. The statement also criticizes recent DEA actions involving DOI and DOC, arguing that criminalization should not precede research, education, and harm reduction. It calls for keeping the substances researchable and treating people who use them outside the criminal justice system.